Skip to content

Coronavirus Infection (COVID-19) and Radical Surgery in Patients With Early-stage Lung Cancer

Effects of Coronavirus Infection (COVID-19) on the Timing and Prognosis of Radical Surgery in Patients With Early-stage Lung Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05684549
Acronym
COVIDLungSurg
Enrollment
2000
Registered
2023-01-13
Start date
2023-01-11
Completion date
2024-12-31
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Infection, Surgery

Keywords

Lung cancer, Surgery, Corona Virus Infection

Brief summary

The goal of this observational study is to learn about the effects of coronavirus infection in patients with early-stage lung cancer. The main question it aims to answer is whether the interval of surgery and COVID-19 infection will affect the surgery and prognosis of the patients.

Interventions

OTHERNo intervention

Observational study, no intervention

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed stage I and stage II lung cancer, who are about to receive wedge resection, segmental resection, sleeve resection, lobectomy, or pneumonectomy under general anaesthesia. * Volunteer to participate in the study with good compliance. Able to complete the observation and follow-up and have signed the informed consent. * ASA score: I-III; * Cardiopulmonary functions meet the requirements of radical operation for lung cancer with normal liver and kidney functions.

Exclusion criteria

* Neurologic, mental illness or mental disorder which is hard to control, poor compliance, unable to cooperate or describe the treatment response; * Clinically diagnosed stage III and stage IV lung cancer or patients who received neoadjuvant treatment before surgery; * Patients developed symptoms alike coronavirus infection but are not confirmed by viral RNA detection by quantitative RT-PCR or antigen testing kits. * Serious heart, lung, liver and kidney dysfunction and unable to tolerate the operation

Design outcomes

Primary

MeasureTime frameDescription
postoperative morbiditypostoperative in-hospital stay up to 30 daysrate of perioperative complications, mainly include: pneumonia, respiratory failure, pulmonary embolism, arrhythmia, sepsis, cerebrovascular accident, myocardial injury, acute kidney injury.

Secondary

MeasureTime frameDescription
operation timeAt operation dayduration of operation
R0 ratepostoperative in-hospital stay up to 30 daysR0 resection rate
postoperative hospital staypostoperative in-hospital stay up to 30 dayslength of postoperative hospitalization
30-day mortalitypostoperative in-hospital stay up to 30 days30-day mortality after surgery
quality of lifepostoperative in-hospital stay up to 30 dayspostoperative quality of life
blood lossAt operation dayblood loss in the operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026